MGC Pharmaceuticals Limited (LON:MXC – Get Rating) was up 5.5% during trading on Wednesday . The company traded as high as GBX 0.47 ($0.01) and last traded at GBX 0.46 ($0.01). Approximately 20,235,677 shares were traded during trading, an increase of 540% from the average daily volume of 3,162,909 shares. The stock had previously closed at GBX 0.44 ($0.01).
Wall Street Analyst Weigh In
Separately, Canaccord Genuity Group reiterated a “speculative buy” rating and set a GBX 2 ($0.02) target price on shares of MGC Pharmaceuticals in a research report on Wednesday, March 22nd.
MGC Pharmaceuticals Stock Performance
The company has a quick ratio of 0.50, a current ratio of 0.39 and a debt-to-equity ratio of 84.03. The business has a 50 day simple moving average of GBX 0.51 and a two-hundred day simple moving average of GBX 0.63. The firm has a market cap of £13.17 million, a PE ratio of -55.00 and a beta of 1.22.
MGC Pharmaceuticals Company Profile
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.
Featured Stories
- Should Cheesecake Factory Stock Be On Your Menu?
- Buffett Reduces Taiwan Semiconductor Stake After This Happened
- Don’t Get Bullish On The S&P 500 Because Of The CPI Report
- Shockwave Medical Gets 10% Jolt, Leads Medical Gear Makers Higher
- Proterra Inc., A Penny Stock To Put On The Watchlist
Receive News & Ratings for MGC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MGC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
